April 4, 2016Current Pharmaceutical Design
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Key result
Prasugrel and ticagrelor reduce ischemic events over clopidogrel in ACS, but increase major bleeding.
Why the study?
Significant research is needed to define the optimal antiplatelet regimen in patients undergoing transcatheter aortic valve implantation and to understand the efficacy and safety of commonly used antiplatelet therapies.
Population
Patients with cardiovascular conditions including those undergoing TAVI and with acute coronary syndrome
Comparison
Aspirin, clopidogrel, prasugrel, and ticagrelor antiplatelet therapies
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
May guide DAPT selection in ACS balancing ischemia versus bleeding; leaves open prospective validation in contemporary cohorts.
Structured PICO
P
Population
Patients with cardiovascular conditions, specifically those undergoing transcatheter aortic valve implantation (TAVI) and those with acute coronary syndrome.
I
Intervention
Antiplatelet therapy (aspirin, clopidogrel, prasugrel, and ticagrelor)
Prasugrel and ticagrelor offer superior ischemic protection over clopidogrel in acute coronary syndrome but increase bleeding risk, while optimal antiplatelet regimens for TAVI remain to be defined.
Cite This Study
Dobesh et al. (2016) conducted a review in Cardiovascular conditions and transcatheter aortic valve implantation (TAVI). Antiplatelet agents (Aspirin, Clopidogrel, Prasugrel, Ticagrelor) was evaluated. Prasugrel and ticagrelor demonstrated superior reductions in ischemic endpoints compared to clopidogrel in dual antiplatelet therapy, but with more major bleeding in acute coronary syndrome patients.